Edwards SAPIEN 3 TAVR:

The leading solution for lifetime management

Edwards SAPIEN 3 TAVR:

The leading solution for lifetime management

Every patient—across all valve sizes and genders—deserves to be considered for comprehensive lifetime management

Recorded Live at ACC24:*

Contemporary results of TAVR with balloon expandable valves including results in small annuli and durability

Hear from your peers about the outcomes that can make an impact on a successful lifetime management strategy for all patients.

Contemporary results with SAPIEN 3 Ultra RESILIA valve

Clinical outcomes of balloon expandable valves in small annuli: the latest data

Durability: what does the patient care about?

TAVR Results in Small Annuli Patients: Early Reactions to New Data

*Edwards sponsored symposium at ACC in Atlanta, Georgia on April 7, 2024.

Real-world evidence from more than 10,000 patients1

SAPIEN 3 Ultra RESILIA valve demonstrated the following results in a large propensity-matched patient population treated at >800 sites:

Excellent procedural outcomes and low complication rates
Statistically significant reduction in PVL for 29 mm SAPIEN 3 Ultra RESILIA THV compared to 29 mm SAPIEN 3 THV
At discharge and 30 days, results showed significantly lower echo-derived mean gradients and higher calculated aortic valve areas
See the new real-world data

Outcomes

Consistent outcomes that matter, starting with the index procedure.1

Explore outcomes ›

Durability

A comprehensive approach to a durable therapy that offers proven long-term patient outcomes.6,9

Explore durability ›

Future Interventions

Making future options possible.7,8

Explore future options ›

References:

1. Stinis CT, Abbas AE, Teirstein P, et al. Real-World Outcomes for the Fifth-Generation Balloon Expandable Transcatheter Heart Valve in the United States. JACC Cardiovasc Interv. Published online February 29, 2024.
2. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. doi: 10.1056/NEJMoa1814052.
3. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023; 389:1949-1960. doi: 10.1056/NEJMoa2307447.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, PARTNER, PARTNER 3, RESILIA, the PARTNER design logo, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

PP--EU-XXXX v1.0